Effect of Omega-3 Polyunsaturated Fatty Acids Treatment on Lipid Pattern of HIV Patients: A Meta-Analysis of Randomized Clinical Trials

• Published in: Marine drugs 2020-06, Vol.18 (6), p.292
• Main Authors: Fogacci, Federica, Strocchi, Enrico, Veronesi, Maddalena, Borghi, Claudio, Cicero, Arrigo F G
• Format: Article
• Language: English
• Subjects: Adult; Analysis; Apolipoprotein B; Apolipoproteins; Bias; Cardiovascular disease; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Clinical trials; Confidence intervals; Density; Drug dosages; Dyslipidemia; Dyslipidemias; Eicosapentaenoic acid; Eicosapentaenoic Acid - therapeutic use; Fatty acids; Fatty Acids, Omega-3 - therapeutic use; Female; high-density lipoprotein cholesterol; HIV; HIV Infections - blood; HIV Infections - drug therapy; Human immunodeficiency virus; Humans; Infections; Lipids; Lipoproteins; Male; Meta-analysis; Middle Aged; Omega-3 polyunsaturated fatty acids; Patients; Polyunsaturated fatty acids; Randomized Controlled Trials as Topic; Ratios; Review; Safety; Serum; Serum levels; Studies; Triglycerides; Triglycerides - blood; Viruses
• ISSN: 1660-3397; 1660-3397
• DOI: 10.3390/md18060292

Even though omega-3 polyunsaturated fatty acids (PUFAs) seem to be effective in the treatment of human immunodeficiency virus (HIV)-associated dyslipidemia, their impact is still debated. For this reason, our aim was to perform a meta-analysis of the clinical evidence available to date. A systematic literature search was conducted in order to identify published clinical trials assessing the effect of PUFAs treatment on serum lipoproteins, and its safety profile. The effect sizes for lipid changes were expressed as mean difference (MD) and 95% confidence interval (CI). For safety analysis, odd ratios and the 95% CI were calculated with the Mantel-Haenszel method. Data were pooled from nine clinical studies comprising overall 578 HIV-affected subjects. Meta-analysis of the data suggested that omega-3 PUFAs significantly reduced triglycerides (TG) (MD = -1.04, 95% CI: -1.5, -0.58 mmol/L, < 0.001), while increasing high-density lipoprotein cholesterol (MD = 0.36, 95% CI: 0.12, 0.61 mmol/L, = 0.004), without affecting serum levels of total cholesterol, very-low- and low-density lipoprotein cholesterol, and apolipoprotein B and A1. Change in TG was significantly associated with eicosapentaenoic acid administered via daily dose. PUFA treatment did not lead to an increased risk of adverse events. In conclusion, PUFAs are safe and exert a significant plasma lipid improving effect in HIV-positive patients.